MiMedx Group (NASDAQ:MDXG) reported its first quarter 2026 operating and financial results after the market close on Tuesday, April 29, posting net sales of $59 million — a figure that fell short of analyst expectations and prompted the company to revise its full-year guidance. The market reacted swiftly, with shares dropping more than 8% in after-hours trading.
First Quarter Results: Revenue and EPS Miss Estimates
For the quarter ended March 31, 2026, MiMedx reported Non-GAAP earnings per share of -$0.05, missing the consensus estimate of -$0.0281 by a significant margin. Revenue came in at $59 million, below the analyst projected $66.3 million. This represents a revenue shortfall of approximately 11% against expectations.
Key financial highlights for Q1 2026:
- Reported Net Sales: $59 million vs. $66.3 million estimated (miss)
- Non-GAAP EPS: -$0.05 vs. -$0.0281 estimated (miss)
- Market Reaction: After-market trading down approximately 8.4%
Guidance Revision and Full-Year Outlook
In conjunction with the earnings release, MiMedx management revised its 2026 net sales and Adjusted EBITDA expectations. While the press release did not specify exact new dollar figures, the revision comes as a clear acknowledgment that the current operating environment or product demand is falling short of prior internal forecasts.
This is a critical point for investors. The current analyst consensus for full-year 2026 revenue stands at approximately $352 million. For the second quarter of 2026, analysts are projecting net sales of roughly $74.9 million. The company's decision to lower its own outlook suggests that achieving these consensus numbers may be more challenging than previously thought, which likely contributed to the negative market reaction.
Recent Price Performance Context
The after-market decline of over 8% extends a period of weakness for the stock. Over the last two weeks, MiMedx shares have fallen by roughly 13.3%, and over the last month, the stock is down nearly 12%. The only recent positive note was a marginal gain of 6.25% over the last week, which appears to have been completely erased by the earnings disappointment. The current price action suggests that investors are reassessing the company's near-term growth trajectory.
Analyst Views and Key Takeaways
While the press release highlighted the company’s product portfolio breadth — including EPIFIX in wound care and AMNIOFIX in surgical applications — the numbers tell the story of a company facing headwinds in the current quarter. The combination of a clear revenue miss, a wider-than-expected EPS loss, and a downward revision to annual guidance is a triple negative that explains the sharp after-market selloff.
For a deeper dive into MiMedx's historical earnings performance and to track future analyst estimates, view the full earnings history and projections here: Earnings Details | Analyst Forecasts
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Readers should conduct their own research and consult with a qualified financial advisor before making any investment decisions.